Author + information
- Rocío González Ferreiro,
- Diego Lopez Otero,
- Ramiro Trillo Nouche,
- Diego Alvarez Iglesias,
- Adrian Cid Menendez,
- Leyre Alvarez Rodriguez,
- Ana Belen Cid Alvarez,
- Juan Carlos Sanmartin Pena and
- Jose Ramon Gonzalez Juanatey
Background: Worsening of renal function is common after trancather aortic valve implantation (TAVI) and is a predictor of adverse outcomes. The evidence of the use of Renal Guard (RG) as protector of contrast-induced nephropathy is limited in patients undergoing TAVI. The aim of our study was to evaluate the role of RG in preventing CIN in patients undergoing TAVI.
Methods and Results: 239 patients undergoing TAVI were included (mean age 82.1 ± 5.8 years, 53.1% women). 58 patients formed the RG group, the rest of patients received intravenous hydratation (IH) with normal saline solution. According to Mehran score, patients were classified as low risk for development of CIN (2.6%, n=6), moderate risk (44.7%, n=105), high risk (43.4%, n=102) and very high risk (9.4%, n=22). CIN was defined according to the VARC-2 definition (AKI). We analyzed patients at high and very high risk of CIN (n=118). 76 patients received IH and 42 RG. Table shows the baseline characteristics of the two groups. Glomerular filtration rate (GFR) was lower in RG group, and there were no significant differences in other renal function parameters like cystatine C. A total of 27 (22.8%) patients developed CIN, 14 (33,3%) in RG group and 13 (17.1%) in IH group, however, this difference was no significant (p=0.066). There were no differences in 30-days mortality. CIN was associated with significantly higher mortality (p=0.001) during the follow-up (median 1.8 years).
Conclusions: In our series, the use of RG compared to intravenous hydratation in patients undergoing TAVI, was not associated with reduced incidence of CIN in patients at high/very high risk (stratified by Mehran score).
Poster Hall, Hall C
Saturday, March 18, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Interventional Cardiology: TAVR 2
Abstract Category: 17. Interventional Cardiology: Aortic Valve Disease
Presentation Number: 1195-180
- 2017 American College of Cardiology Foundation